Key Drivers
- Strong Profitability
- High Leverage
- Weak Cash Conversion
AIAI Summary
PAHC's acquisition-driven earnings step-up is now a cash-flow-and-deleveraging test: despite strong FY2026 results, slowing FY2027 EBITDA growth, ~3x leverage, weak free-cash-flow conversion, and Brazil regulatory risk make the shares actionable only if management converts synergies into materially higher FCF and lower net debt.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Profitability
- •High Leverage
- •Weak Cash Conversion
PAHC is profitable and reasonably valued, but high leverage, weak free-cash-flow conversion, and dividends exceeding FCF warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support test
- •Weak momentum
PAHC remains bearish last month, with support at $34.45–$34.60 needing to hold to avoid further downside toward $34.00–$34.25, while a move above $35.60–$36.20 would signal improvement.
Sharp retreat from the $39.92
Sentiment & News
Key News Insights:
- •Record sales
- •Earnings beat
- •Zoetis integration
Phibro's record FY2026 sales, strong earnings beat, and Zoetis portfolio integration support positive growth momentum heading into FY2027.
Results and strategic initiatives strengthen PAHC's growth outlook and investor appeal
Similar Companies in Healthcare
Other companies in the same sector with AI ratings